Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. (TSHA) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001806310 · TSHA · NASDAQ · as of Jun 8, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001806310 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has submitted 391 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001806310, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Taysha Gene Therapies, Inc.'s most comprehensive regulatory disclosure. The most recent Taysha Gene Therapies, Inc. 10-K was filed on 2026-03-19 for fiscal year ending 2026. Historical TSHA 10-K annual reports are available from 2020 through 2026.
Investors researching Taysha Gene Therapies, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
TSHA SEC Filings · 8 questionsTaysha Gene Therapies, Inc. (TSHA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 391 filings and access original documents at no cost. Taysha Gene Therapies, Inc.'s CIK is 0001806310.